Cargando…

Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019

While confirmed cases of the deadly coronavirus disease 2019 (COVID-19) have exceeded 4.7 million globally, scientists are pushing forward with efforts to develop vaccines and treatments in an attempt to slow the pandemic and lessen the disease's damage. Although no proven effective therapies f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Di Cosimo, Serena, Malfettone, Andrea, Pérez-García, José M., Llombart-Cussac, Antonio, Miceli, Rosalba, Curigliano, Giuseppe, Cortés, Javier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Current Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7269953/ https://www.ncbi.nlm.nih.gov/pubmed/32544799 http://dx.doi.org/10.1016/j.ejca.2020.05.026

Ejemplares similares

Commentary: SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China
por: Di Cosimo, Serena, et al.
Publicado: (2020)

Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone, do it!
por: Omarini, Claudia, et al.
Publicado: (2020)

Nobody dares stopping clinical research, not even COVID-19
por: Malfettone, Andrea, et al.
Publicado: (2021)

Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects
por: Gion, María, et al.
Publicado: (2021)

The Value of Case Reports in Systematic Reviews from Rare Diseases. The Example of Enzyme Replacement Therapy (ERT) in Patients with Mucopolysaccharidosis Type II (MPS-II)
por: Sampayo-Cordero, Miguel, et al.
Publicado: (2020)

The Impact of Excluding Nonrandomized Studies From Systematic Reviews in Rare Diseases: “The Example of Meta-Analyses Evaluating the Efficacy and Safety of Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis”
por: Sampayo-Cordero, Miguel, et al.
Publicado: (2021)

Can Increased Recovery Rates from Coronavirus be explained by Prevalence of ADHD? An Analysis at the US Statewide Level
por: Arbel, Yuval, et al.
Publicado: (2020)

Coronavirus disease (COVID-19) outbreak and phase 1 trials: should we consider a specific patient management?
por: Postel-Vinay, Sophie, et al.
Publicado: (2020)

Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER)
por: Tougeron, David, et al.
Publicado: (2021)

Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2– breast cancer
por: Curigliano, Giuseppe, et al.
Publicado: (2023)

Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial
por: López-Miranda, Elena, et al.
Publicado: (2020)

Are all cyclin-dependent kinases 4/6 inhibitors created equal?
por: Marra, Antonio, et al.
Publicado: (2019)

Coronavirus 2019 Silver Linings
por: Santosa, Amelia, et al.
Publicado: (2020)

Seasons of Coronavirus Disease 2019
por: Macnofsky, Robin, et al.
Publicado: (2021)

A single-arm study design with non-inferiority and superiority time-to-event endpoints: a tool for proof-of-concept and de-intensification strategies in breast cancer
por: Sampayo-Cordero, Miguel, et al.
Publicado: (2023)

Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases
por: Sampayo-Cordero, Miguel, et al.
Publicado: (2019)

Coronavirus disease 2019 fatigue in the allergy clinic
por: Forester, Joseph P., et al.
Publicado: (2021)

Coronavirus disease 2019 vaccines: perspectives and update
por: Kaushik, S.K., et al.
Publicado: (2021)

Coronavirus disease 2019 and the gut–lung axis
por: Zhou, Dan, et al.
Publicado: (2021)

Secukinumab - First in Class Interleukin-17A Inhibitor for the Treatment of Psoriasis
por: Godse, Kiran
Publicado: (2017)

Potential association of mast cells with coronavirus disease 2019
por: Theoharides, Theoharis C.
Publicado: (2021)

Is There Still a Place for Tocilizumab in Coronavirus Disease 2019?
por: Klopfenstein, Timothée, et al.
Publicado: (2021)

Immunotherapy for early triple negative breast cancer: research agenda for the next decade
por: Tarantino, Paolo, et al.
Publicado: (2022)

Disease-directed engineering for physiology-driven treatment interventions in neurological disorders
por: Wood, Thomas, et al.
Publicado: (2019)

Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design
por: Sampayo-Cordero, Miguel, et al.
Publicado: (2020)

The research community must meet the coronavirus disease 2019 challenge
por: Singh, Poonam Khetrapal
Publicado: (2020)

The Time for Universal Masking of the Public for Coronavirus Disease 2019 Is Now
por: Gandhi, Monica, et al.
Publicado: (2020)

Addressing children’s health amid the coronavirus disease 2019 pandemic
por: Choe, Young June, et al.
Publicado: (2020)

An overview of the effect of bioaerosol size in coronavirus disease 2019 transmission
por: Guzman, Marcelo I.
Publicado: (2020)

Coronavirus Disease 2019 May Affect Dental Implant Integration
por: Block, Michael S.
Publicado: (2021)

Coronavirus Disease 2019 and the Case to Cover Undocumented Immigrants in California
por: Torres-Pinzon, Diana L., et al.
Publicado: (2020)

Pembrolizumab in combination with tocilizumab in high-risk hospitalized patients with COVID-19 (COPERNICO): A randomized proof-of-concept phase II study
por: Sánchez-Conde, Matilde, et al.
Publicado: (2022)

A Perspective on Yoga as a Preventive Strategy for Coronavirus Disease 2019
por: Nagarathna, R, et al.
Publicado: (2020)

Coronavirus Disease 2019 (COVID-19) in Kenya: Preparedness, response and transmissibility
por: Aluga, Martin A.
Publicado: (2020)

Public Health Measures to Slow Community Spread of Coronavirus Disease 2019
por: Cowling, Benjamin J, et al.
Publicado: (2020)

Coronavirus 2019 and health systems affected by protracted conflict: The case of Syria
por: Abbara, Aula, et al.
Publicado: (2020)

Statins as candidate therapeutic agents for coronavirus disease 2019 (COVID-19)
por: Li, Sheng-De, et al.
Publicado: (2021)

Future pulmonary rehabilitation perspectives following coronavirus disease 2019 in China
por: Zhao, Hong-Mei, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor-related Endocrinopathies
por: Lu, Difei, et al.
Publicado: (2022)

Hallmarks of Resistance to Immune-Checkpoint Inhibitors
por: Karasarides, Maria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r7c30h1eu8no21q34ddrv1f54n